Research Analysts’ Recent Ratings Changes for Illumina (ILMN)

Several analysts have recently updated their ratings and price targets for Illumina (NASDAQ: ILMN):

• 7/15/2026 – Illumina had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $140.00 to $190.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 7/1/2026 – Illumina had its price target raised by Piper Sandler from $170.00 to $200.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Illumina had its price target raised by Guggenheim from $180.00 to $200.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Illumina is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $185.00 price target on the stock.
• 6/25/2026 – Illumina was upgraded by Sanford C. Bernstein to “hold”.
• 6/24/2026 – Illumina had its price target raised by Barclays PLC from $122.00 to $145.00. They now have an “underweight” rating on the stock.
• 6/10/2026 – Illumina was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $185.00 price target on the stock, up from $125.00.
• 6/3/2026 – Illumina was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/1/2026 – Illumina had its price target raised by Guggenheim from $170.00 to $180.00. They now have a “buy” rating on the stock.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider owned 20,953 shares of the company’s stock, valued at $3,771,540. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by company insiders.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.